Outcomes with @entity7774 -converting Enzyme Inhibitors vs Other Antihypertensive Agents in XXXX Blacks.

@entity1 @entity64 @entity712 @entity101 @entity7774 @entity6662 @entity460 @entity583 @entity204
BACKGROUND: @entity7774 -converting enzyme inhibitors are used widely in the treatment of @entity1 with @entity101 . However, their efficacy in @entity101 blacks when compared with other antihypertensive agents is not well established. METHODS: We performed a cohort study of @entity1 using data from a clinical data warehouse of 434,646 @entity1 from New York City's Health and Hospitals Corporation from January 2004 to December 2009. @entity1 were divided into the following comparison groups: @entity7774 -converting enzyme inhibitors vs @entity460 channel blockers, @entity7774 -converting enzyme inhibitors vs @entity6662 diuretics, and @entity7774 -converting enzyme inhibitors vs b-blockers. The primary outcome was a composite of @entity204 , @entity583 , and @entity64 . Secondary outcomes included the individual components and @entity712 . RESULTS: In the propensity score-matched @entity7774 -converting enzyme inhibitors vs @entity460 channel blocker comparison cohort (4506 blacks in each group), @entity7774 -converting enzyme inhibitors were associated with a higher risk of primary outcome (hazard ratio [ @entity712 ], 1.45; 95% confidence interval [CI], 1.19-1.77; P  = .0003), @entity583 ( @entity712 , 3.40; 95% CI, 1.25-9.22; P  = .02), @entity64 ( @entity712 , 1.82; 95% CI, 1.29-2.57; P  = .001), and @entity712 ( @entity712 , 1.77; 95% CI, 1.30-2.42; P  = .0003) when compared with @entity460 channel blockers. For the @entity7774 -converting enzyme inhibitors vs @entity6662 diuretics comparison (5337 blacks in each group), @entity7774 -converting enzyme inhibitors were associated with a higher risk of primary outcome ( @entity712 , 1.65; 95% CI, 1.33-2.05; P < .0001), @entity204 ( @entity712 , 1.35; 95% CI, 1.03-1.76; P  = .03), @entity583 ( @entity712 , 4.00; 95% CI, 1.34-11.96; P  = .01), @entity64 ( @entity712 , 1.97; 95% CI, 1.34-2.92; P  = .001), and @entity712 ( @entity712 , 3.00; 95% CI, 1.99-4.54; P < .0001). For the @entity7774 -converting enzyme inhibitors vs b-blocker comparison, the outcomes between the groups were not significantly different. CONCLUSIONS: In a real-world cohort of @entity101 blacks, @entity7774 -converting enzyme inhibitors were associated with a higher risk of cardiovascular events when compared with @entity460 channel blockers or @entity6662 diuretics.
